Search

Your search keyword '"Listì, Angela"' showing total 153 results
Start Over Author "Listì, Angela"
153 results on '"Listì, Angela"'

1. Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience

Author

Pepe, Francesco, Russo, Gianluca, Venuta, Alessandro, Scimone, Claudia, Nacchio, Mariantonia, Pisapia, Pasquale, Goteri, Gaia, Barbisan, Francesca, Chiappetta, Caterina, Pernazza, Angelina, Campagna, Domenico, Giordano, Marco, Perrone, Giuseppe, Sabarese, Giovanna, Altimari, Annalisa, de Biase, Dario, Tallini, Giovanni, Calistri, Daniele, Chiadini, Elisa, Capelli, Laura, Santinelli, Alfredo, Gulini, Anna Elisa, Pierpaoli, Elisa, Badiali, Manuela, Murru, Stefania, Murgia, Riccardo, Guerini Rocco, Elena, Venetis, Konstantinos, Fusco, Nicola, Morotti, Denise, Gianatti, Andrea, Furlan, Daniela, Rossi, Giulio, Melocchi, Laura, Russo, Maria, De Luca, Caterina, Palumbo, Lucia, Simonelli, Saverio, Maffè, Antonella, Francia di Celle, Paola, Venesio, Tiziana, Scatolini, Maria, Grosso, Enrico, Orecchia, Sara, Fassan, Matteo, Balistreri, Mariangela, Zulato, Elisabetta, Reghellin, Daniela, Lazzari, Elena, Santacatterina, Maria, Piredda, Maria Liliana, Riccardi, Manuela, Laurino, Licia, Roz, Elena, Longo, Domenico, Romeo, Daniela Petronilla, Fazzari, Carmine, Moreno-Manuel, Andrea, Puglia, Giuseppe Diego, Prjibelski, Andrey D., Shafranskaya, Daria, Righi, Luisella, Listì, Angela, Vitale, Domenico, Iaccarino, Antonino, Malapelle, Umberto, and Troncone, Giancarlo

Published
2024
Full Text
View/download PDF

2. Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity

Author

Bersani, Francesca, Picca, Francesca, Morena, Deborah, Righi, Luisella, Napoli, Francesca, Russo, Mariangela, Oddo, Daniele, Rospo, Giuseppe, Negrino, Carola, Castella, Barbara, Volante, Marco, Listì, Angela, Zambelli, Vanessa, Benso, Federica, Tabbò, Fabrizio, Bironzo, Paolo, Monteleone, Emanuele, Poli, Valeria, Pietrantonio, Filippo, Di Nicolantonio, Federica, Bardelli, Alberto, Ponzetto, Carola, Novello, Silvia, Scagliotti, Giorgio V., and Taulli, Riccardo

Published
2023
Full Text
View/download PDF

4. Supplementary Figure 3 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

Author

Passiglia, Francesco, primary, Righi, Luisella, primary, Bironzo, Paolo, primary, Listì, Angela, primary, Farinea, Giovanni, primary, Capelletto, Enrica, primary, Novello, Silvia, primary, Merlini, Alessandra, primary, and Scagliotti, Giorgio V., primary

Published
2024
Full Text
View/download PDF

6. Supplementary Figure 2 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

Author

Passiglia, Francesco, primary, Righi, Luisella, primary, Bironzo, Paolo, primary, Listì, Angela, primary, Farinea, Giovanni, primary, Capelletto, Enrica, primary, Novello, Silvia, primary, Merlini, Alessandra, primary, and Scagliotti, Giorgio V., primary

Published
2024
Full Text
View/download PDF

7. Supplementary Figure 1 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

Author

Passiglia, Francesco, primary, Righi, Luisella, primary, Bironzo, Paolo, primary, Listì, Angela, primary, Farinea, Giovanni, primary, Capelletto, Enrica, primary, Novello, Silvia, primary, Merlini, Alessandra, primary, and Scagliotti, Giorgio V., primary

Published
2024
Full Text
View/download PDF

8. Supplementary Table 1 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

Author

Passiglia, Francesco, primary, Righi, Luisella, primary, Bironzo, Paolo, primary, Listì, Angela, primary, Farinea, Giovanni, primary, Capelletto, Enrica, primary, Novello, Silvia, primary, Merlini, Alessandra, primary, and Scagliotti, Giorgio V., primary

Published
2024
Full Text
View/download PDF

9. Supplementary Table 2 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

Author

Passiglia, Francesco, primary, Righi, Luisella, primary, Bironzo, Paolo, primary, Listì, Angela, primary, Farinea, Giovanni, primary, Capelletto, Enrica, primary, Novello, Silvia, primary, Merlini, Alessandra, primary, and Scagliotti, Giorgio V., primary

Published
2024
Full Text
View/download PDF

12. Actionable Non-Small Cell Lung Cancer Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients with Advanced Lung Cancer (Epropa)

Author

Passiglia, Francesco, primary, Listì, Angela, additional, Bironzo, Paolo, additional, Merlini, Alessandra, additional, Benso, Federica, additional, Napoli, Francesca, additional, Barbu, Francesca Alice, additional, Zambelli, Vanessa, additional, Tabbò, Fabrizio, additional, Reale, Maria Lucia, additional, Sini, Claudio, additional, Roca, Elisa, additional, Taveggia, Paola Adriana, additional, Simionato, Francesca, additional, Buffoni, Lucio, additional, Mazilu, Laura, additional, Barbieri, Vito, additional, Pignataro, Daniele, additional, Araújo, Antonio, additional, Paz Ares, Luis, additional, Felip, Enriqueta, additional, Secen, Nevena, additional, Comanescu, Alina, additional, Madi, Kleida, additional, Bettini, Anna Cecilia, additional, Scotti, Vieri, additional, Linardou, Helena, additional, Mohorcic, Katja, additional, Meoni, Giulia, additional, Volante, Marco, additional, Malapelle, Umberto, additional, Vallone, Stefania, additional, Scagliotti, Giorgio Vittorio, additional, Righi, Luisella, additional, and Novello, Silvia, additional

Published
2024
Full Text
View/download PDF

18. Additional file 1 of Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity

Author

Bersani, Francesca, Picca, Francesca, Morena, Deborah, Righi, Luisella, Napoli, Francesca, Russo, Mariangela, Oddo, Daniele, Rospo, Giuseppe, Negrino, Carola, Castella, Barbara, Volante, Marco, Listì, Angela, Zambelli, Vanessa, Benso, Federica, Tabbò, Fabrizio, Bironzo, Paolo, Monteleone, Emanuele, Poli, Valeria, Pietrantonio, Filippo, Di Nicolantonio, Federica, Bardelli, Alberto, Ponzetto, Carola, Novello, Silvia, Scagliotti, Giorgio V., and Taulli, Riccardo

Abstract

Additional file 1: Fig. S1. CircMET RNA in silico analysis. Fig. S2. circMET expression and cellular localization. Fig. S3. Generation and characterization of HCC827 and WiDr drug-resistant subpopulations. Fig.S4. CircMET evaluation reveals HER/MET codependency and mirrors combination therapy response in vitro. Fig.S5. Heatmap of concordance among assays applied to the primary samples. Table S1. Cancer cell lines assessed for MET and circMET expression, with indication of MET amplification status. Table S2. Clinical information of the primary samples included in the study. Table S3. Summary of the somatic alterations detected with Guardant360 Biopsy-Free Tumor Sequencing in case #5 upon relapse to osimertinib. Table S4. List of primers and probes.

Published
2023
Full Text
View/download PDF

19. Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer

Author

Mariniello, Annapaola, primary, Tabbò, Fabrizio, additional, Indellicati, Davide, additional, Tesauro, Martina, additional, Rezmives, Nicole Alessia, additional, Reale, Maria Lucia, additional, Listì, Angela, additional, Capelletto, Enrica, additional, Carnio, Simona, additional, Bertaglia, Valentina, additional, Mecca, Caterina, additional, Consito, Lorena, additional, De Filippis, Marco, additional, Bungaro, Maristella, additional, Paratore, Chiara, additional, Di Maio, Massimo, additional, Passiglia, Francesco, additional, Righi, Luisella, additional, Sangiolo, Dario, additional, Novello, Silvia, additional, Geuna, Massimo, additional, and Bironzo, Paolo, additional

Published
2022
Full Text
View/download PDF

20. RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center

Author

Luca, Caterina De, primary, Pepe, Francesco, additional, Pisapia, Pasquale, additional, Iaccarino, Antonino, additional, Righi, Luisella, additional, Listì, Angela, additional, Russo, Gianluca, additional, Campione, Severo, additional, Pagni, Fabio, additional, Nacchio, Mariantonia, additional, Conticelli, Floriana, additional, Russo, Maria, additional, Fabozzi, Teresa, additional, Vigliar, Elena, additional, Bellevicine, Claudio, additional, Rocco, Danilo, additional, Laudati, Stefano, additional, Iannaci, Giuseppe, additional, Daniele, Bruno, additional, Gridelli, Cesare, additional, Cortinovis, Diego Luigi, additional, Novello, Silvia, additional, Molina-Vila, Miguel Angel, additional, Rosell, Rafael, additional, Troncone, Giancarlo, additional, and Malapelle, Umberto, additional

Published
2022
Full Text
View/download PDF

23. Real‐world retrospective study of KRAS mutations in advanced non–small cell lung cancer in the era of immunotherapy.

Author

Bironzo, Paolo, Cani, Massimiliano, Jacobs, Francesca, Napoli, Valerio M., Listì, Angela, Passiglia, Francesco, Righi, Luisella, Di Maio, Massimo, Novello, Silvia, and Scagliotti, Giorgio V.

Subjects
NON-small-cell lung carcinoma, RAS oncogenes, PROGRESSION-free survival, IMMUNOTHERAPY, GENETIC mutation
Abstract

Background: KRAS mutation‐positive (KRAS‐positive), advanced nonsmall‐cell lung cancer (NSCLC) is characterized by a poor prognosis. KRAS mutations are extremely heterogeneous from a biologic point of view, and real‐world data by mutation subtype in the era of immunotherapy are still incomplete. Methods: The objective of this study was to retrospectively analyze all consecutive patients with advanced/metastatic, KRAS‐positive NSCLC who were diagnosed at a single academic institution since the advent of immunotherapy. The authors report on the natural history of the disease as well as the efficacy of first‐line treatments in the entire cohort and by KRAS mutation subtypes as well as the presence/absence of co‐mutations. Results: From March 2016 to December 2021, the authors identified 199 consecutive patients who had KRAS‐positive, advanced or metastatic NSCLC. The median overall survival (OS) was 10.7 months (95% confidence interval [CI], 8.5–12.9 months), and there were no differences by mutation subtype. Among 134 patients who received first‐line treatment, the median OS was 12.2 months (95% CI, 8.3–16.1 months), and the median progression‐free survival was 5.6 months (95% CI, 4.5–6.6 months). At multivariate analysis, only an Eastern Cooperative Oncology Group performance status of 2 was associated with significantly shorter progression‐free survival and OS. Conclusions: KRAS‐positive, advanced NSCLC is characterized by a poor prognosis despite the introduction of immunotherapy. Survival was not associated with KRAS mutation subtype. Plain Language Summary: This study evaluated the efficacy of systemic therapies for advanced/metastatic nonsmall cell lung cancer harboring KRAS mutations, along with the potential predictive and prognostic role of mutation subtypes. The authors found that advanced/metastatic, KRAS‐positive nonsmall cell lung cancer is characterized by a poor prognosis and that first‐line treatment efficacy is not related to different KRAS mutations, although a numerically shorter median progression‐free survival was observed in patients who had p.G12D and p.G12A mutations.These results underline the need for novel treatment options in this population, such as next‐generation KRAS inhibitors, which are in clinical and preclinical development. Despite the introduction of immunotherapy, KRAS‐positive, advanced non–small cell lung cancer is still characterized by a poor prognosis. In this study, KRAS mutation subtypes did not influence survival. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Diagnostics of BAP1-Tumor Predisposition Syndrome by a Multitesting Approach: A Ten-Year-Long Experience

Author

Sculco, Marika, primary, La Vecchia, Marta, additional, Aspesi, Anna, additional, Clavenna, Michela Giulia, additional, Salvo, Michela, additional, Borgonovi, Giulia, additional, Pittaro, Alessandra, additional, Witel, Gianluca, additional, Napoli, Francesca, additional, Listì, Angela, additional, Grosso, Federica, additional, Libener, Roberta, additional, Maconi, Antonio, additional, Rena, Ottavio, additional, Boldorini, Renzo, additional, Giachino, Daniela, additional, Bironzo, Paolo, additional, Maffè, Antonella, additional, Alì, Greta, additional, Elefanti, Lisa, additional, Menin, Chiara, additional, Righi, Luisella, additional, Tampieri, Cristian, additional, Scagliotti, Giorgio Vittorio, additional, Dianzani, Caterina, additional, Ferrante, Daniela, additional, Migliore, Enrica, additional, Magnani, Corrado, additional, Mirabelli, Dario, additional, Matullo, Giuseppe, additional, and Dianzani, Irma, additional

Published
2022
Full Text
View/download PDF

29. Repositioning PARP inhibitors in the treatment of thoracic malignancies

Author

Passiglia, Francesco, primary, Reale, Maria Lucia, additional, Cetoretta, Valeria, additional, Parlagreco, Elena, additional, Jacobs, Francesca, additional, Listì, Angela, additional, Righi, Luisella, additional, Bironzo, Paolo, additional, Novello, Silvia, additional, and Scagliotti, Giorgio Vittorio, additional

Published
2021
Full Text
View/download PDF

31. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients

Author

Malapelle, U, Passiglia, F, Cremolini, C, Reale, M, Pepe, F, Pisapia, P, Avallone, A, Cortinovis, D, De Stefano, A, Fassan, M, Fontanini, G, Galetta, D, Lauricella, C, Listì, A, Loupakis, F, Pagni, F, Pietrantonio, F, Pilotto, S, Righi, L, Bianchi, A, Parra, H, Tiseo, M, Verzè, M, Troncone, G, Novello, S, Malapelle, Umberto, Passiglia, Francesco, Cremolini, Chiara, Reale, Maria Lucia, Pepe, Francesco, Pisapia, Pasquale, Avallone, Antonio, Cortinovis, Diego, De Stefano, Alfonso, Fassan, Matteo, Fontanini, Gabriella, Galetta, Domenico, Lauricella, Calogero, Listì, Angela, Loupakis, Fotios, Pagni, Fabio, Pietrantonio, Filippo, Pilotto, Sara, Righi, Luisella, Bianchi, Andrea Sartore, Parra, Hector Soto, Tiseo, Marcello, Verzè, Michela, Troncone, Giancarlo, Novello, Silvia, Malapelle, U, Passiglia, F, Cremolini, C, Reale, M, Pepe, F, Pisapia, P, Avallone, A, Cortinovis, D, De Stefano, A, Fassan, M, Fontanini, G, Galetta, D, Lauricella, C, Listì, A, Loupakis, F, Pagni, F, Pietrantonio, F, Pilotto, S, Righi, L, Bianchi, A, Parra, H, Tiseo, M, Verzè, M, Troncone, G, Novello, S, Malapelle, Umberto, Passiglia, Francesco, Cremolini, Chiara, Reale, Maria Lucia, Pepe, Francesco, Pisapia, Pasquale, Avallone, Antonio, Cortinovis, Diego, De Stefano, Alfonso, Fassan, Matteo, Fontanini, Gabriella, Galetta, Domenico, Lauricella, Calogero, Listì, Angela, Loupakis, Fotios, Pagni, Fabio, Pietrantonio, Filippo, Pilotto, Sara, Righi, Luisella, Bianchi, Andrea Sartore, Parra, Hector Soto, Tiseo, Marcello, Verzè, Michela, Troncone, Giancarlo, and Novello, Silvia

Abstract

Rat sarcoma (RAS) oncogenes have intensively been investigated during the last decades. Taking into account all human tumours, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene is the most frequently mutated (about 22%) among the three isoforms, followed by Neuroblastoma RAS Viral Oncogene Homolog (NRAS) (8%) and Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) (3%). In the last years, careful attention has been paid on KRAS and NRAS gene mutations in non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC) patients because of their prognostic and predictive roles. In particular, a large body of literature data has been generated investigating clinical outcomes of targeted treatments in NSCLC and CRC KRAS- and NRAS-mutated patients. The latest evidences are here reviewed, providing also an overview of the real-world RAS mutation testing practice across different Italian laboratories. On this basis, we propose a knowledge-based system, www.rasatlas.com, to support the healthcare personnel in the management of patients featuring RAS gene mutations in the landscape of precision oncology.

Published
2021

32. RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer

Author

De Luca, C, Pepe, F, Iaccarino, A, Pisapia, P, Righi, L, Listì, A, Greco, L, Gragnano, G, Campione, S, De Dominicis, G, Pagni, F, Sgariglia, R, Nacchio, M, Tufano, R, Conticelli, F, Vigliar, E, Bellevicine, C, Cortinovis, D, Novello, S, Molina-Vila, M, Rosell, R, Troncone, G, Malapelle, U, De Luca, Caterina, Pepe, Francesco, Iaccarino, Antonino, Pisapia, Pasquale, Righi, Luisella, Listì, Angela, Greco, Lorenza, Gragnano, Gianluca, Campione, Severo, De Dominicis, Gianfranco, Pagni, Fabio, Sgariglia, Roberta, Nacchio, Mariantonia, Tufano, Rossella, Conticelli, Floriana, Vigliar, Elena, Bellevicine, Claudio, Cortinovis, Diego Luigi, Novello, Silvia, Molina-Vila, Miguel Angel, Rosell, Rafael, Troncone, Giancarlo, Malapelle, Umberto, De Luca, C, Pepe, F, Iaccarino, A, Pisapia, P, Righi, L, Listì, A, Greco, L, Gragnano, G, Campione, S, De Dominicis, G, Pagni, F, Sgariglia, R, Nacchio, M, Tufano, R, Conticelli, F, Vigliar, E, Bellevicine, C, Cortinovis, D, Novello, S, Molina-Vila, M, Rosell, R, Troncone, G, Malapelle, U, De Luca, Caterina, Pepe, Francesco, Iaccarino, Antonino, Pisapia, Pasquale, Righi, Luisella, Listì, Angela, Greco, Lorenza, Gragnano, Gianluca, Campione, Severo, De Dominicis, Gianfranco, Pagni, Fabio, Sgariglia, Roberta, Nacchio, Mariantonia, Tufano, Rossella, Conticelli, Floriana, Vigliar, Elena, Bellevicine, Claudio, Cortinovis, Diego Luigi, Novello, Silvia, Molina-Vila, Miguel Angel, Rosell, Rafael, Troncone, Giancarlo, and Malapelle, Umberto

Abstract

Gene fusions represent novel predictive biomarkers for advanced non-small cell lung cancer (NSCLC). In this study, we validated a narrow NGS gene panel able to cover therapeutically-relevant gene fusions and splicing events in advanced-stage NSCLC patients. To this aim, we first assessed minimal complementary DNA (cDNA) input and the limit of detection (LoD) in different cell lines. Then, to evaluate the feasibility of applying our panel to routine clinical samples, we retrospectively selected archived lung adenocarcinoma histological and cytological (cell blocks) samples. Overall, our SiRe RNA fusion panel was able to detect all fusions and a splicing event harbored in a RNA pool diluted up to 2 ng/µL. It also successfully analyzed 46 (95.8%) out of 48 samples. Among these, 43 (93.5%) out of 46 samples reproduced the same results as those obtained with conventional techniques. Intriguingly, the three discordant results were confirmed by a CE-IVD automated real-time polymerase chain reaction (RT-PCR) analysis (Easy PGX platform, Diatech Pharmacogenetics, Jesi, Italy). Based on these findings, we conclude that our new SiRe RNA fusion panel is a valid and robust tool for the detection of clinically relevant gene fusions and splicing events in advanced NSCLC.

Published
2021

34. Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations

Author

Bironzo, Paolo, primary, Reale, Maria Lucia, additional, Sperone, Tessa, additional, Tabbò, Fabrizio, additional, Caglio, Andrea, additional, Listì, Angela, additional, Passiglia, Francesco, additional, Di Maio, Massimo, additional, Righi, Luisella, additional, Bussolino, Federico, additional, Scagliotti, Giorgio V., additional, and Novello, Silvia, additional

Published
2021
Full Text
View/download PDF

35. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients

Author

Malapelle, Umberto, primary, Passiglia, Francesco, additional, Cremolini, Chiara, additional, Reale, Maria Lucia, additional, Pepe, Francesco, additional, Pisapia, Pasquale, additional, Avallone, Antonio, additional, Cortinovis, Diego, additional, De Stefano, Alfonso, additional, Fassan, Matteo, additional, Fontanini, Gabriella, additional, Galetta, Domenico, additional, Lauricella, Calogero, additional, Listì, Angela, additional, Loupakis, Fotios, additional, Pagni, Fabio, additional, Pietrantonio, Filippo, additional, Pilotto, Sara, additional, Righi, Luisella, additional, Bianchi, Andrea Sartore, additional, Parra, Hector Soto, additional, Tiseo, Marcello, additional, Verzè, Michela, additional, Troncone, Giancarlo, additional, and Novello, Silvia, additional

Published
2021
Full Text
View/download PDF

36. RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer

Author

De Luca, Caterina, primary, Pepe, Francesco, additional, Iaccarino, Antonino, additional, Pisapia, Pasquale, additional, Righi, Luisella, additional, Listì, Angela, additional, Greco, Lorenza, additional, Gragnano, Gianluca, additional, Campione, Severo, additional, De Dominicis, Gianfranco, additional, Pagni, Fabio, additional, Sgariglia, Roberta, additional, Nacchio, Mariantonia, additional, Tufano, Rossella, additional, Conticelli, Floriana, additional, Vigliar, Elena, additional, Bellevicine, Claudio, additional, Cortinovis, Diego Luigi, additional, Novello, Silvia, additional, Molina-Vila, Miguel Angel, additional, Rosell, Rafael, additional, Troncone, Giancarlo, additional, and Malapelle, Umberto, additional

Published
2021
Full Text
View/download PDF

39. Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients

Author

Passiglia, Francesco, primary, Galvano, Antonio, additional, Castiglia, Marta, additional, Incorvaia, Lorena, additional, Calò, Valentina, additional, Listì, Angela, additional, Mazzarisi, Salvatore, additional, Perez, Alessandro, additional, Gallina, Giuseppe, additional, Rizzo, Sergio, additional, Soto Parra, Hector, additional, Bazan, Viviana, additional, and Russo, Antonio, additional

Published
2019
Full Text
View/download PDF

40. Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway

Author

La Paglia, Laura, Listì, Angela, Caruso, Stefano, Amodeo, Valeria, Passiglia, Francesco, Bazan, Viviana, and Fanale, Daniele

Subjects
Article Subject
Abstract

The angiopoietin-like 4 (ANGPTL4) protein belongs to a superfamily of secreted proteins structurally related to factors modulating angiogenesis known as angiopoietins. At first, ANGPTL4 has been identified as an adipokine exclusively involved in lipid metabolism, because of its prevalent expression in liver and adipose tissue. This protein regulates lipid metabolism by inhibiting lipoprotein lipase (LPL) activity and stimulating lipolysis of white adipose tissue (WAT), resulting in increased levels of plasma triglycerides (TG) and fatty acids. Subsequently, ANGPTL4 has been shown to be involved in several nonmetabolic and metabolic conditions, both physiological and pathological, including angiogenesis and vascular permeability, cell differentiation, tumorigenesis, glucose homoeostasis, lipid metabolism, energy homeostasis, wound healing, inflammation, and redox regulation. The transcriptional regulation of ANGPTL4 can be modulated by several transcription factors, including PPARα, PPARβ/δ, PPARγ, and HIF-1α, and nutritional and hormonal conditions. Several studies showed that high levels of ANGPTL4 are associated with poor prognosis in patients with various solid tumors, suggesting an important role in cancer onset and progression, metastasis, and anoikis resistance. Here, we have discussed the potential role of ANGPTL4 in mediating the cross talk between metabolic syndromes, such as diabetes and obesity, and cancer through regulation of its expression by PPARs.

Published
2017
Full Text
View/download PDF

43. “Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors

Author

Incorvaia, Lorena, primary, Passiglia, Francesc, additional, Rizzo, Sergio, additional, Galvano, Antonio, additional, Listì, Angela, additional, Barraco, Nadia, additional, Maragliano, Rossella, additional, Calò, Valentina, additional, Natoli, Clara, additional, Ciaccio, Marcello, additional, Bazan, Viviana, additional, and Russo, Antonio, additional

Published
2016
Full Text
View/download PDF

44. Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?

Author

Fanale, Daniele, Bronte, Giuseppe, Passiglia, Francesco, Calò, Valentina, Castiglia, Marta, Di Piazza, Florinda, Barraco, Nadia, Cangemi, Antonina, Catarella, Maria Teresa, Insalaco, Lavinia, Listì, Angela, Maragliano, Rossella, Massihnia, Daniela, Perez, Alessandro, Toia, Francesca, Cicero, Giuseppe, and Bazan, Viviana

Subjects
Article Subject
Abstract

Microtubules are dynamic and structural cellular components involved in several cell functions, including cell shape, motility, and intracellular trafficking. In proliferating cells, they are essential components in the division process through the formation of the mitotic spindle. As a result of these functions, tubulin and microtubules are targets for anticancer agents. Microtubule-targeting agents can be divided into two groups: microtubule-stabilizing, and microtubule-destabilizing agents. The former bind to the tubulin polymer and stabilize microtubules, while the latter bind to the tubulin dimers and destabilize microtubules. Alteration of tubulin-microtubule equilibrium determines the disruption of the mitotic spindle, halting the cell cycle at the metaphase-anaphase transition and, eventually, resulting in cell death. Clinical application of earlier microtubule inhibitors, however, unfortunately showed several limits, such as neurological and bone marrow toxicity and the emergence of drug-resistant tumor cells. Here we review several natural and synthetic microtubule-targeting agents, which showed antitumor activity and increased efficacy in comparison to traditional drugs in various preclinical and clinical studies. Cryptophycins, combretastatins, ombrabulin, soblidotin, D-24851, epothilones and discodermolide were used in clinical trials. Some of them showed antiangiogenic and antivascular activity and others showed the ability to overcome multidrug resistance, supporting their possible use in chemotherapy.

Published
2015
Full Text
View/download PDF

46. Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus

Author

Cabibi, Daniela, primary, Caruso, Stefano, additional, Bazan, Viviana, additional, Castiglia, Marta, additional, Bronte, Giuseppe, additional, Ingrao, Sabrina, additional, Fanale, Daniele, additional, Cangemi, Antonina, additional, Calò, Valentina, additional, Listì, Angela, additional, Incorvaia, Lorena, additional, Galvano, Antonio, additional, Pantuso, Gianni, additional, Fiorentino, Eugenio, additional, Castorina, Sergio, additional, and Russo, Antonio, additional

Published
2016
Full Text
View/download PDF

47. KRAS and BRAF as prognostic biomarkers in patients undergoing surgical resection of colorectal cancer liver metastasis: A systematic review and meta-analysis.

Author

Passiglia, Francesco, primary, Bronte, Giuseppe, additional, Galvano, Antonio, additional, Rizzo, Sergio, additional, Listì, Angela, additional, Barraco, Nadia, additional, Insalaco, Lavinia, additional, Maragliano, Rossella, additional, Bronte, Enrico, additional, Musso, Emmanuela, additional, Guarini, Aurelia, additional, Castellana, Luisa, additional, Castiglia, Marta, additional, Calò, Valentina, additional, Vieni, Salvatore, additional, Cicero, Giuseppe, additional, Rolfo, Christian Diego, additional, Bazan, Viviana, additional, and Russo, Antonio, additional

Published
2016
Full Text
View/download PDF

49. Nintedanib in NSCLC: evidence to date and place in therapy

Author

Bronte, Giuseppe, primary, Passiglia, Francesco, additional, Galvano, Antonio, additional, Barraco, Nadia, additional, Listì, Angela, additional, Castiglia, Marta, additional, Rizzo, Sergio, additional, Fiorentino, Eugenio, additional, Bazan, Viviana, additional, and Russo, Antonio, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results